SELLAS Life Sciences Group, Inc.
SLS
$1.56
-$0.05-3.11%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -36.97% | 16.27% | -16.38% | -22.13% | 10.40% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -37.14% | -1.94% | -21.71% | -15.79% | -14.50% |
| Operating Income | 37.14% | 1.94% | 21.71% | 15.79% | 14.50% |
| Income Before Tax | 39.23% | 17.20% | 23.30% | 15.50% | 13.80% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 39.23% | 17.20% | 23.30% | 15.50% | 13.80% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.23% | 17.20% | 23.30% | 15.50% | 13.80% |
| EBIT | 37.14% | 1.94% | 21.71% | 15.79% | 14.50% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 68.99% | 65.51% | 68.15% | 58.43% | 54.70% |
| Normalized Basic EPS | 68.97% | 59.90% | 68.14% | 58.44% | 54.70% |
| EPS Diluted | 68.99% | 65.51% | 68.15% | 58.31% | 54.70% |
| Normalized Diluted EPS | 68.97% | 59.90% | 68.14% | 58.44% | 54.70% |
| Average Basic Shares Outstanding | 95.84% | 140.18% | 140.71% | 103.30% | 90.31% |
| Average Diluted Shares Outstanding | 95.84% | 140.18% | 140.71% | 103.30% | 90.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |